La Vanguardia and Expansión Catalunya, among other media, have devoted an articleto Ona Therapeutics, the new IRB Barcelona spin-off that has completed a seed financing round of 1.5 million euros, invested entirely by Sabadell Asabys. With this injection of capital, the spin-off created by IRB Barcelona, ICREA and the researchers Salvador Aznar Benitah and Valerie Vanhooren, will start up activity with the development of a new drug for the treatment of metastatic cancer.
Link to La Vanguardia
Link to Expansión Catalunya
The weekly supplement Dinero of La Vanguardia has published an article about Ona Therapeutics, the spin-off created by IRB Barcelona, ICREA and the researchers Salvador Aznar-Benitah and Valerie Vanhooren, with funding from Sabadell Asabys. Based on results published by Aznar in the journal Nature in 2017, the company aims to find a new treatment for metastatic cancer.
